- Conditions
- Ovarian Cancer
- Interventions
- Farletuzumab, Carboplatin, Taxane, Farletuzumab-matched placebo
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 91 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 17,807
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
- Interventions
- PF-08634404, Chemotherapy, Nivolumab
- Biological · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 83
- States / cities
- Atascadero, California • Burbank, California • Encino, California + 68 more
- Conditions
- B Cell Precursor Acute Lymphoblastic Leukemia
- Interventions
- Blinatumomab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 13
- States / cities
- Clovis, California • Duarte, California • Chicago, Illinois + 10 more
- Conditions
- Neuroblastoma
- Interventions
- irinotecan hydrochloride, vincristine sulfate, iobenguane I 131
- Drug · Radiation
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
- Conditions
- Lung Transplant Rejection
- Interventions
- Belumosudil, Azithromycin, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
- Conditions
- Carotid Stenosis, Ischemic Stroke, Transient Ischemic Attack
- Interventions
- intensive medical therapy
- Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 11
- States / cities
- Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 7 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- AMV564, AMV564 in combination with pembrolizumab
- Biological · Combination Product
- Lead sponsor
- Amphivena Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 10
- States / cities
- San Francisco, California • Chicago, Illinois • Baltimore, Maryland + 7 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Inhaled Nitric Oxide 75 mcg/kg IBW/hr, Placebo
- Drug
- Lead sponsor
- Bellerophon Pulse Technologies
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 33 more
- Conditions
- HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma
- Interventions
- LJM716
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts • Houston, Texas + 1 more
- Conditions
- Seasonal Influenza
- Interventions
- mRNA-1010, Fluarix Quadrivalent
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 22,502 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 134
- States / cities
- Athens, Alabama • Glendale, Arizona • Phoenix, Arizona + 110 more
- Conditions
- Colorectal Cancer
- Interventions
- DHA-paclitaxel
- Drug
- Lead sponsor
- Theradex
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
- Conditions
- Severe Hepatic Veno-Occlusive Disease
- Interventions
- Defibrotide
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 22
- States / cities
- Duarte, California • Palo Alto, California • Denver, Colorado + 19 more
- Conditions
- Acute Pain
- Interventions
- IV Acetaminophen, IV Control
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 1 Day to 2 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Orange, California • San Diego, California + 19 more
- Conditions
- Solid Tumors
- Interventions
- axitinib, crizotinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2023
- U.S. locations
- 18
- States / cities
- Orange, California • San Francisco, California • Santa Monica, California + 9 more
- Conditions
- Hypertension
- Interventions
- lorundrostat, Placebo
- Drug
- Lead sponsor
- Mineralys Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,076 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 128
- States / cities
- Birmingham, Alabama • Foley, Alabama • Chandler, Arizona + 101 more
- Conditions
- Heparin, Thrombocytopenia, Electronic Health Records
- Interventions
- Electronic medical record order panel and resident involvement
- Other
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Lymphoma, T-Cell, Peripheral
- Interventions
- Romidepsin, Ixazomib
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 4 more
- Conditions
- Solid Tumor, Adult
- Interventions
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6
- Combination Product
- Lead sponsor
- Trishula Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- HM15211, Placebo of HM15211
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Chula Vista, California + 37 more
- Conditions
- Major Depressive Disorder
- Interventions
- CERC-301, Placebo
- Drug
- Lead sponsor
- Avalo Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 13
- States / cities
- Newport Beach, California • Alpharetta, Georgia • Chicago, Illinois + 10 more
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
- Interventions
- Bupropion 150 mg XL, Placebo
- Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 362
- States / cities
- Anaheim, California • Antioch, California • Baldwin Park, California + 262 more
- Conditions
- Stroke, Weakness, Muscle, Coordination Lack
- Interventions
- Bilateral, Unilateral
- Other
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- HER2-positive Breast Cancer
- Interventions
- Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
- Radiation · Drug
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 1,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2037
- U.S. locations
- 413
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 286 more
- Conditions
- HIV, Patient Acceptance of Health Care
- Interventions
- Supportive Care
- Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois